ImmuCell Co. (NASDAQ:ICCC) Sees Significant Growth in Short Interest

ImmuCell Co. (NASDAQ:ICCC) saw a significant increase in short interest during the month of November. As of November 15th, there was short interest totalling 23,600 shares, an increase of 490.0% from the October 31st total of 4,000 shares. Based on an average daily trading volume, of 34,600 shares, the short-interest ratio is currently 0.7 days. Approximately 0.4% of the shares of the stock are short sold.

ImmuCell Price Performance

Shares of ImmuCell stock opened at $3.72 on Thursday. ImmuCell has a 12 month low of $3.34 and a 12 month high of $5.59. The company has a current ratio of 3.11, a quick ratio of 1.44 and a debt-to-equity ratio of 0.36. The stock has a 50 day moving average of $3.62 and a 200 day moving average of $3.97. The firm has a market cap of $33.15 million, a PE ratio of -7.44 and a beta of 0.56.

ImmuCell Company Profile

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.